Pharming receives EMA approval of new facility for expansion of RUCONEST® production
Pharming announces the placement of €125 million senior unsecured convertible bonds due 2025
RUCONEST® (conestat alfa)
RUCONEST® (conestat alfa) is a recombinant human C1 esterase inhibitor approved for the treatment of angioedema attacks in patients with HAE
View our financial calendar and what conferences, meetings and congresses we will visit in 2019 on our upcoming events page.
Our innovative technology and processes are aimed at purification and formulation of recombinant products. We are continuously looking for highly talented and motivated individuals to join our team.